Multiple Myeloma
Showing NaN - NaN of 99
Fluoroquinolone Resistance Prevalence Study
Recruiting
- Multiple Myeloma
-
Washington, District of Columbia
- +1 more
Apr 10, 2023
Multiple Myeloma Trial in Spain, United States (BB2121, CC-220, BMS-986405)
Recruiting
- Multiple Myeloma
- BB2121
- +2 more
-
Birmingham, Alabama
- +33 more
Jan 26, 2023
Multiple Myeloma Trial in Worldwide (Selinexor, Dexamethasone)
Completed
- Multiple Myeloma
-
Birmingham, Alabama
- +60 more
Jan 24, 2023
Multiple Myeloma Trial in Worldwide (JNJ-68284528, Pomalidomide, Bortezomib)
Active, not recruiting
- Multiple Myeloma
- JNJ-68284528
- +4 more
-
Birmingham, Alabama
- +87 more
Jan 17, 2023
Multiple Myeloma Trial in Worldwide (Teclistamab, Daratumumab, Pomalidomide)
Active, not recruiting
- Multiple Myeloma
- Teclistamab
- +5 more
-
Birmingham, Alabama
- +26 more
Jan 17, 2023
Multiple Myeloma Trial in Worldwide (Daratumumab IV, Lenalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Daratumumab IV
- +3 more
-
Birmingham, Alabama
- +211 more
Jan 17, 2023
Multiple Myeloma Trial in Hackensack (Thalidomide+Melphalan +Bortezomib+stem cell transplant)
Completed
- Multiple Myeloma
- Thalidomide+Melphalan +Bortezomib+stem cell transplant
-
Hackensack, New JerseyJohn Theurer Cancer Center at Hackensack University Medical Cent
Dec 16, 2022
Multiple Myeloma Trial in United States (Isatuximab, Carfilzomib, Dexamethasone)
Recruiting
- Multiple Myeloma
- Isatuximab
- +2 more
-
San Francisco, California
- +3 more
Dec 24, 2022
Multiple Myeloma, Auto Stem Cell Transplant Trial in Hackensack (Bortezomib)
Active, not recruiting
- Multiple Myeloma
- Auto Stem Cell Transplant
-
Hackensack, New JerseyJohn Theurer Cancer Center @ Hackensack University Medical Cente
Dec 23, 2022
Multiple Myeloma Trial in Worldwide (bb2121, Daratumumab, Pomalidomide)
Active, not recruiting
- Multiple Myeloma
- bb2121
- +8 more
-
Birmingham, Alabama
- +59 more
Dec 13, 2022
Multiple Myeloma Trial in Worldwide (Belantamab mafodotin, Lenalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Belantamab mafodotin
- +3 more
-
Birmingham, Alabama
- +25 more
Dec 9, 2022
Multiple Myeloma Trial in Worldwide (Elranatamab (PF-06863135))
Active, not recruiting
- Multiple Myeloma
- Elranatamab (PF-06863135)
-
Beverly Hills, California
- +75 more
Oct 4, 2022
Multiple Myeloma Trial in Worldwide (Carfilzomib, Dexamethasone)
Completed
- Multiple Myeloma
-
Scottsdale, Arizona
- +139 more
Sep 9, 2022
Multiple Myeloma Trial in United States (Cilta-cel, Lymphodepleting Therapy (Cyclophosphamide and Fludarabine))
Recruiting
- Multiple Myeloma
- Cilta-cel
- Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
-
Duarte, California
- +23 more
Aug 1, 2022
Multiple Myeloma Trial in Greece, Korea, Republic of, United States (Belantamab mafodotin)
Recruiting
- Multiple Myeloma
- Belantamab mafodotin
-
Tucson, Arizona
- +21 more
Jul 20, 2022
Multiple Myeloma Trial in Hackensack (Bortezomib)
Terminated
- Multiple Myeloma
-
Hackensack, New JerseyThe Cancer Center at Hackensack University Medical Center
Jun 24, 2022
Multiple Myeloma Trial in Worldwide (bb2121)
Active, not recruiting
- Multiple Myeloma
- bb2121
-
San Francisco, California
- +47 more
Jul 18, 2022
Multiple Myeloma Trial in United States (bb2121, Fludarabine, Cyclophosphamide)
Active, not recruiting
- Multiple Myeloma
- bb2121
- +3 more
-
Scottsdale, Arizona
- +19 more
Jul 7, 2022